Advertisement
NomosLogic at BIO International Convention 2026NomosLogic will be at the BIO International Convention in San Diego, June 22 to 25, 2026. The four days at the San Diego Convention Center bring together roughly 20,000 leaders across biotechnology, pharmaceuticals, regulation, and investment.
We are showing up to participate in the conversations that matter, to meet the people building the next decade of the field, and to open partnership discussions with operators whose work compounds with ours.
This is the right conference, in the right year, for the work we are doing.
Why BIO 2026 Matters
The 2026 program lands at a structural inflection point.
AI applied to health, personalized medicine, next-generation biotherapeutics, intellectual property, regulation, and translational research are all on the agenda. More importantly, they are all at the stage where the standards being set now will define how the field operates for the next decade.
The agencies are codifying. The capital markets are recalibrating. Institutional buyers are tightening what they accept as production-ready.
The conversations happening in San Diego in June will shape decisions that matter long after the convention closes.
The deterministic standard for clinical decision infrastructure is one of those decisions, and we intend to be substantive in the conversations that determine where it lands.
What We Bring to the Conversation
The platform is in production today, serving four execution domains from one sovereign substrate: clinical genomics, consumer genomics, payer infrastructure, and pharma research.
The underlying engines operate at scale, including over 1 million Clinical Logic Objects and deterministic genome resolution in under 30 seconds, with multi-omic fusion across genomic and standard clinical lab data in under 90 seconds.
The architectural commitment underneath the platform is what makes it different.
Every clinical assertion is rule-based, reproducible, and cryptographically anchored to the rule version that produced it. AI operates at the interpretation and communication surface where it belongs. The clinical decision layer is deterministic.
That distinction is not cosmetic. It is the structural property that makes the platform auditable under FDA scrutiny, defensible in clinical practice, and resilient through the regulatory and capital-market shifts the field is moving into.
Who We Want to Meet
The four days are short, and the convention is large. We are coming with a clear set of conversations worth having.
Pharma and biotech research teams working on programs where pharmacogenomic decision support, multi-modal data fusion, or deterministic variant interpretation would change trial design, candidate prioritization, or post-market surveillance.
Health systems and clinical labs evaluating how to bring auditable, reproducible interpretation infrastructure into their operations without compromising clinical credibility. The platform integrates standard genomic and clinical lab data and delivers synthesis through SMART on FHIR directly into the EHR.
Payer organizations examining how pharmacogenomic-guided prescribing changes the economics of adverse drug events, polypharmacy, and avoidable hospitalizations. The economics are real. The missing piece has been infrastructure that makes those signals legible at the payer level.
Investors and corporate development teams mapping the emerging deterministic infrastructure category. NomosLogic operates in a category that most diligence frameworks do not yet model cleanly. That is a signal that the category is forming and the number of true entrants remains limited.
Thought leaders, policy voices, scientists, authors, and media working on clinical AI governance, pharmacogenomic standards, intellectual property in molecular medicine, and the broader question of how next-generation clinical decision infrastructure should be defined.
How to Connect
For partnership discussions, sales conversations, and general business development, reach:
Jai DeJong SVP of Business Development and Sales [email protected]
For CEO-to-CEO conversations, scientific discussions, editorial inquiries, and media:
Matt Hardy Founder and CEO [email protected]
We are scheduling structured BIO Partnering meetings through the official platform and holding additional time for substantive conversations that come through direct outreach.
Closing
We will be in San Diego for the conversations that define what comes next.
#BIO2026 #BIOInternational #SanDiego #ClinicalGenomics #Pharmacogenomics #PrecisionMedicine #deterministicconvergence #MolecularMedicine #biotech #ClinicalExcellence #HealthInnovation #NomosLogic #BIO2026 #BIOInternational #sandiego #bioinformatics #bioscience #MolecularMedicineInfrastructure
Advertisement
Event Venue
San Diego Convention Center, 111 W Harbor Dr,San Diego, California, United States
Tickets
Concerts, fests, parties, meetups - all the happenings, one place.
